SOURCE: PolyPeptide Laboratories Group
November 19, 2007 11:00 ET
PolyPeptide Laboratories Group Acquires NeoMPS
Leading Manufacturer of Peptides Expands Capacity and Worldwide Operations
HOOFDDORP, THE NETHERLANDS--(Marketwire - November 19, 2007) - PolyPeptide Laboratories Group,
a leading global provider of custom and generic GMP-grade peptides for a
range of pharmaceutical and biotechnology applications, today announced its
acquisition of peptide manufacturing group NeoMPS from Isochem, the fine
chemicals subsidiary of the French Groupe SNPE. NeoMPS operates facilities
in France (Strasbourg) and the United States (San Diego).
The acquisition bolsters PolyPeptide Laboratories' manufacturing capacity
and capabilities, from small-scale custom peptides for research to
large-scale peptides for therapeutic applications. Such capabilities
complement the Group's long-established core strength in GMP manufacturing,
and will help service a range of projects from conception through
commercialization. NeoMPS also manufactures cosmetic peptides and brings
an extensive catalog business.
"The addition of NeoMPS to the PolyPeptide Laboratories Group is a great
fit, and offers customers of both companies an even more comprehensive
range of services for every stage of development," said Jane Salik, CEO of
PolyPeptide Laboratories Group. "With this acquisition, we are expanding
our capacity to meet the needs of customers who demand the most robust,
scalable and cost efficient peptide manufacturing available."
NeoMPS CEO Serge Plaué added, "By joining PolyPeptide Laboratories Group,
we are able to offer customers our combined, highly complementary
experience and capabilities. Together, we can provide an unparalleled range
With the NeoMPS acquisition, PolyPeptide Laboratories Group operates GMP
facilities in the United States (Torrance and San Diego, California),
France (Strasbourg), Denmark (Hillerod) and Sweden (Malmo). Ongoing
expansions in Malmo, Torrance, and Strasbourg are continuing as planned.
The Group is also constructing a soon-to-be-launched GMP facility in
Mumbai, India that will be focused on generic peptides.
The acquisition announced today will not affect ongoing activities at the
NeoMPS facilities in Strasbourg and San Diego. Harmonization of procedures
to ensure consistency, continuity and quality within the expanded
PolyPeptide Laboratories Group will be implemented in the coming months.
NeoMPS was formed by the 2004 merger of France-based Neosystem and
California-based Multiple Peptide Systems, both of which were launched as
independent companies in 1986. Details regarding financial aspects of
today's announced acquisition by PolyPeptide Laboratories Group were not
Peptides, like proteins, are naturally-occurring chains of amino acids
involved in virtually every life process. They help regulate body functions
such as the release of hormones and the regulation of blood sugar levels.
Advances in genomics and proteomics have boosted the demand for peptides,
particularly in the development of pharmaceuticals. Synthetic peptides
serve as the active pharmaceutical ingredient (API) in peptide-based drugs
that treat diabetes, HIV/AIDS, endocrine and nervous system disorders, and
other health conditions.
About PolyPeptide Laboratories Group
PolyPeptide Laboratories Group is a leading provider of custom and generic
GMP-grade peptides for a range of pharmaceutical and biotechnology
applications. With corporate roots that began in the 1950s, the Group was
launched formally in 1996. Today, it operates a growing international
network of peptide manufacturing facilities. Its world-class chemists and
support personnel offer an unparalleled range of services for clients of
every size and at every stage of product development. More information
about PolyPeptide Laboratories Group is available at www.PolyPeptide.com.